<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135249</url>
  </required_header>
  <id_info>
    <org_study_id>STU 112016-060</org_study_id>
    <nct_id>NCT03135249</nct_id>
  </id_info>
  <brief_title>Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
  <acronym>SUPPRESS</acronym>
  <official_title>Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a sequential combination therapy of natalizumab
      and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in
      patients with relapsing-remitting multiple sclerosis (RRMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if treatment with alemtuzumab after natalizumab reduces the ARR in patients with
      RRMS. The goal of this trial is to establish a disease-free state over a 24 months period in
      patients who received the natalizumab-alemtuzumab sequential therapy. The target population
      for this study are RRMS patients nearing the end of their natalizumab treatment
      regimen.Participants will be recruited from four different sites. Patients who meet all
      inclusion/exclusion criteria will be eligible for enrollment in the study.

      Alemtuzumab (LemtradaÂ®) will be administered at a dose of 12 mg/d by intravenous (i.v.)
      infusion every day for five consecutive days within 14 days of the last dose of natalizumab.
      After 12 months, patients will be treated with a second course of alemtuzumab 12 mg/d by
      intravenous (i.v.) infusion every day for three consecutive days, and participants will be
      followed open-label for another 12 months per standard of care. Outside the scope of this
      study, the intention is to follow all study participants in participating centers long-term,
      and to record disease activity and treatment response.

      Natalizumab treatment sequesters leukocytes out of the central nervous system (CNS) into the
      peripheral blood. Immediate sequential alemtuzumab therapy will deplete these cells more
      completely than alemtuzumab monotherapy, and prevent reactivation of disease activity
      previously treated with natalizumab. Thus, investigators hypothesize that sequential
      natalizumab - alemtuzumab therapy will prevent disease activation after cessation of
      natalizumab, and will provide sustained disease remission in many patients.

      Clinical follow up by the treating physician will occur at months 0, 3, 6, 9, 12, 18 and 24
      or immediately following clinical exacerbations months. During clinical visits, comprehensive
      medical history data will be obtained by the treating physician. Clinical visits due to
      suspected exacerbations associated with CNS (central nervous system) demyelination, and
      associated diagnostic studies and treatments, will be covered under the medical standard of
      care by third party payers. A recommendation to reevaluate the patient within 3 months
      following the clinical event to assess for extent of recovery will be made.

      Standardized MRI studies of the brain will be performed at 0, 6, 12 and 24 months. Clinical
      imaging studies of the brain will be performed during or immediately following the onset of a
      clinical exacerbation will be performed at the discretion of the site PI with scan costs
      covered under the medical standard of care. An end of study clinical MRI of the brain with
      and without contrast will be recommended to study participants at week 96 as medical standard
      of care.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>To determine if treatment with alemtuzumab after natalizumab maintains or reduces the ARR in patients with RRMS. The goal of this trial is to establish a disease-free state over a 24 months period in patients who received the natalizumab-alemtuzumab sequential therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized relapse rate (ARR) from the time of cessation of natalizumab treatment.</measure>
    <time_frame>2 years</time_frame>
    <description>To determine if treatment with alemtuzumab after natalizumab maintains or reduces the ARR in patients with RRMS. The goal of this trial is to establish a disease-free state over a 24 months period in patients who received the natalizumab-alemtuzumab sequential therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free period</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the freedom of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging outcomes</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the number of new/enlarging T2 lesions, and the number of gadolinium (Gd)-enhancing lesions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Neurological disability outcome</measure>
    <time_frame>24 months</time_frame>
    <description>The Expanded Disability Status Scale (EDSS) will be utilized to measure the accumulation of neurological disability</description>
  </other_outcome>
  <other_outcome>
    <measure>Anterior visual pathway outcome</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the effect on the retinal nerve fiber layer (RNFL), optic coherence tomography (OCT) will be performed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life outcome</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life (QoL) will be measures by a pre-defined, self-administered testing battery.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis (MS)</condition>
  <arm_group>
    <arm_group_label>Alemtuzumab treatment.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:
Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.
Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alemtuzumab</intervention_name>
    <description>Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.</description>
    <arm_group_label>Alemtuzumab treatment.</arm_group_label>
    <other_name>Lemtrada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 60 years, inclusive.

          2. Diagnosis of relapsing forms of MS using revised McDonald Criteria1.

          3. Expanded Disability Status Scale (EDSS) 0 - 5.5 (note: functional system changes in
             cerebral (or mental) functions and in bowel and bladder functions not used in
             determining EDSS for protocol eligibility).

          4. Has had a minimum of 12 monthly doses of continuous natalizumab therapy (300 mg/d).

          5. Understands English, and gives informed consent.

        Exclusion Criteria:

          1. Natalizumab failure based on clinician's discretion.

          2. Any prior exposure to alemtuzumab.

          3. Progressive MS.

          4. A diagnosis of Progressive multifocal leukoencephalopathy (PML).

          5. Known hypersensitivity to alemtuzumab.

          6. Initiation of new immunosuppressant treatment after the subject becomes
             protocol-eligible (except for corticosteroids) or enrollment in a concurrent trial
             with immuno-active pharmacotherapies.

          7. Uncontrolled diabetes mellitus defined as HbA1c &gt; 8% and/or requiring intensive
             management.

          8. History of cytopenia consistent with the diagnosis of myelodysplastic syndrome.

          9. Clinically significant autoimmune disease other than MS that may affect the CNS,
             including neuromyelitis optica (NMO), systemic lupus erythematosus (SLE), or Behcet
             disease.

         10. Active hepatitis B or C infection or evidence of cirrhosis.

         11. HIV positivity.

         12. Uncontrolled viral, fungal, or bacterial infection.

         13. Positive pregnancy test or inability or unwillingness to use effective means of birth
             control. Effective birth control is defined as:

               1. Refraining from all acts of vaginal intercourse (abstinence),

               2. Consistent use of birth control pills,

               3. Tubal sterilization or male partner who has undergone vasectomy

               4. Placement of intrauterine device

               5. Use, with every act of intercourse, of a diaphragm with contraceptive jelly
                  and/or condoms with contraceptive foam.

         14. Presence of metallic objects implanted in the body that would preclude the ability of
             the subject to safely have MRI exams.

         15. Psychiatric illness, mental deficiency, or cognitive dysfunction making compliance
             with treatment or informed consent impossible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olaf Stuve, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):911-23.</citation>
    <PMID>16510745</PMID>
  </reference>
  <reference>
    <citation>Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2;354(9):899-910.</citation>
    <PMID>16510744</PMID>
  </reference>
  <reference>
    <citation>StÃ¼ve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006 Oct;63(10):1383-7.</citation>
    <PMID>17030653</PMID>
  </reference>
  <reference>
    <citation>StÃ¼ve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006 May;59(5):743-7.</citation>
    <PMID>16634029</PMID>
  </reference>
  <reference>
    <citation>StÃ¼ve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Tervaert JW, De Baets M, MacManus D, Miller DH, RadÃ¼ EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009 Feb 3;72(5):396-401. doi: 10.1212/01.wnl.0000327341.89587.76. Epub 2008 Nov 5.</citation>
    <PMID>18987352</PMID>
  </reference>
  <reference>
    <citation>Kowarik MC, Pellkofer HL, Cepok S, Korn T, KÃ¼mpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology. 2011 Apr 5;76(14):1214-21. doi: 10.1212/WNL.0b013e3182143564.</citation>
    <PMID>21464424</PMID>
  </reference>
  <reference>
    <citation>del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-DeMasters BK, StÃ¼ve O. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol. 2008 Dec;65(12):1596-603. doi: 10.1001/archneur.65.12.noc80051. Epub 2008 Oct 13.</citation>
    <PMID>18852339</PMID>
  </reference>
  <reference>
    <citation>Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.</citation>
    <PMID>22591293</PMID>
  </reference>
  <reference>
    <citation>Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol. 2016 Aug;22(4):533-5. doi: 10.1007/s13365-016-0427-6. Epub 2016 Feb 3. Erratum in: J Neurovirol. 2016 Aug;22(4):536-7.</citation>
    <PMID>26843383</PMID>
  </reference>
  <reference>
    <citation>Berger JR, Fox RJ. Erratum to: Reassessing the risk of natalizumab-associated PML. J Neurovirol. 2016 Aug;22(4):536-537.</citation>
    <PMID>27026534</PMID>
  </reference>
  <reference>
    <citation>O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 May 31;76(22):1858-65. doi: 10.1212/WNL.0b013e31821e7c8a. Epub 2011 May 4.</citation>
    <PMID>21543733</PMID>
  </reference>
  <reference>
    <citation>Krumbholz M, Meinl I, KÃ¼mpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008 Oct 21;71(17):1350-4. doi: 10.1212/01.wnl.0000327671.91357.96.</citation>
    <PMID>18936427</PMID>
  </reference>
  <reference>
    <citation>KivisÃ¤kk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009 Jun 2;72(22):1922-30. doi: 10.1212/WNL.0b013e3181a8266f.</citation>
    <PMID>19487650</PMID>
  </reference>
  <reference>
    <citation>Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.</citation>
    <PMID>23122652</PMID>
  </reference>
  <reference>
    <citation>Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.</citation>
    <PMID>23122650</PMID>
  </reference>
  <reference>
    <citation>Hale G, Rye PD, Warford A, Lauder I, Brito-Babapulle A. The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol. 1993 Mar;23(2):189-205.</citation>
    <PMID>7685389</PMID>
  </reference>
  <reference>
    <citation>Xia MQ, Tone M, Packman L, Hale G, Waldmann H. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol. 1991 Jul;21(7):1677-84.</citation>
    <PMID>1711975</PMID>
  </reference>
  <reference>
    <citation>Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol. 1995 Jan;7(1):69-77.</citation>
    <PMID>7718516</PMID>
  </reference>
  <reference>
    <citation>Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, Hale G, Alexander DR. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol. 2000 Apr;12(4):505-16.</citation>
    <PMID>10744652</PMID>
  </reference>
  <reference>
    <citation>Stauch D, Dernier A, Sarmiento Marchese E, Kunert K, Volk HD, Pratschke J, Kotsch K. Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity. PLoS One. 2009;4(3):e4709. doi: 10.1371/journal.pone.0004709. Epub 2009 Mar 5.</citation>
    <PMID>19266059</PMID>
  </reference>
  <reference>
    <citation>Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan;253(1):98-108. Epub 2005 Jul 27.</citation>
    <PMID>16044212</PMID>
  </reference>
  <reference>
    <citation>CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.</citation>
    <PMID>18946064</PMID>
  </reference>
  <reference>
    <citation>Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009 Oct;128(2):260-70. doi: 10.1111/j.1365-2567.2009.03115.x.</citation>
    <PMID>19740383</PMID>
  </reference>
  <reference>
    <citation>Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011 Mar 15;186(6):3762-9. doi: 10.4049/jimmunol.1000303. Epub 2011 Feb 4.</citation>
    <PMID>21296976</PMID>
  </reference>
  <reference>
    <citation>Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DA, Fahey MT, Coles AJ. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):298-304. doi: 10.1136/jnnp-2011-300826. Epub 2011 Nov 5.</citation>
    <PMID>22056965</PMID>
  </reference>
  <reference>
    <citation>Cossburn MD, Harding K, Ingram G, El-Shanawany T, Heaps A, Pickersgill TP, Jolles S, Robertson NP. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology. 2013 Jan 1;80(1):55-61. doi: 10.1212/WNL.0b013e31827b5927. Epub 2012 Dec 12.</citation>
    <PMID>23243077</PMID>
  </reference>
  <reference>
    <citation>Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Alemtuzumab more effective than interferon Î²-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.</citation>
    <PMID>22442431</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

